QIAGEN NV

ISIN: NL0015001WM6 WKN: N72482149 Asset Class: Stock

48.00 Company 2024/08/15 22:00:02 46.00 **Price** 46.43 44.00 USD **Difference** 42.00 0.83%(0.38) 40.00 **Contact Details** 38.00 **QIAGEN NV** Tel: +31-77-355-66-00 36.00 Fax: + Hulsterweg 82 Web: http://www.qiagen.com 09.2023 11.2023 01.2024 03.2024 05.2024 07.2024

Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Financial figures, Fiscal year: from 01.01. to 31.12.

5912 PL Venlo E-mail: qiagen@qiagen.com

| | 20 | 2023 | | 2022 | | 2021 | |
|--------------------------------|---------------|------------------------|---------------|------------------------|---------------|------------------------|--|
| Financial figures | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity | |
| Current assets | 2,147,560,000 | | 2,393,952,000 | | 2,109,602,000 | | |
| Common stock capital | | 2,702,000 | | 2,702,000 | | 2,702,000 | |
| Fixed assets | 3,967,630,000 | | 3,893,783,000 | | 4,037,352,000 | | |
| Equity capital of a company | | 3,807,764,000 | | 3,466,611,000 | | 3,096,550,000 | |
| Cash and cash equivalents | 668,084,000 | | 730,669,000 | | 880,516,000 | | |
| Accrued liabilities | | 12,100,000 | | 11,900,000 | | 0 | |
| Other assets | - | | - | | - | | |
| Current liabilities | | 1,079,293,000 | | 974,523,000 | | 1,517,470,000 | |
| Prepayments and accrued income | - | | - | | - | | |
| Non-current liabilities | | 1,228,133,000 | | 1,846,601,000 | | 1,532,934,000 | |
| Different income | | - | | - | | - | |
| Other liabilities | | 202,346,000 | | 273,897,000 | | 324,665,000 | |
| Total assets | 6,115,190,000 | 6,115,190,000 | 6,287,735,000 | 6,287,735,000 | 6,146,954,000 | 6,146,954,000 | |

Balance notes

| | 2023 | 2022 | 2021 |
|---------------------|---------|---------|---------|
| Accounting standard | US-GAAP | US-GAAP | US-GAAP |
| Employees | 5,967 | 6,178 | 6,028 |
| Equity ratio | 62.27% | 55.13% | 50.38% |
| Debt-equity ratio | 60.60% | 81.38% | 98.51% |

Others

| | 2023 | 2022 | 2021 |
|------------------|--------|--------|--------|
| Tax Expense Rate | 20.59% | 17.44% | 18.09% |

QIAGEN NV

ISIN: NL0015001WM6 WKN: N72482149 Asset Class: Stock

| Income statement | | | |
|--|---------------|---------------|---------------|
| | 2023 | 2022 | 2021 |
| Turnover | 1,965,311,000 | 2,141,518,000 | 2,251,657,000 |
| Net income | 341,303,000 | 423,211,000 | 512,599,000 |
| EBIT | 367,644,457 | 489,493,810 | 610,051,673 |
| Operating income before taxes | 429,809,000 | 512,601,000 | 625,833,000 |
| Cash Flow | 459,455,000 | 715,264,000 | 639,001,000 |
| Net interest income | 25,582,000 | -25,600,000 | -44,922,000 |
| Research and development expenses | 198,511,000 | 189,859,000 | 189,964,000 |
| Income taxes | 88,506,000 | 89,390,000 | 113,234,000 |
| Result from investments in subsidaries, associates and other | - | - | - |
| Revenues per employee | 299,556 | 315,266 | 339,728 |

| Board of Directors | |
|---------------------------|-------------------------------|
| Lawrence Rosen | Chairman of Supervisory Board |
| Elaine Mardis | Member of Supervisory Board |
| Eva Pisa | Member of Supervisory Board |
| Metin Colpan | Member of Supervisory Board |
| Ross Levine | Member of Supervisory Board |
| Toralf Haag | Member of Supervisory Board |
| Bert van Meurs | Member of Supervisory Board |
| Elizabeth Tallett | Member of Supervisory Board |
| Eva van Pelt | Member of Supervisory Board |
| Stephen Rusckowski | Member of Supervisory Board |

| Members of Management Board | | |
|-------------------------------|--|--|
| | | |
| Chairman of Managing Board | | |
| Member of Executive Committee | | |
| | | |